Key result
Expression of a dominant negative mutant of c-Fos (AFos) abrogated the pathological gene profile induced by hypertrophic agonists but did not change the myocyte growth response.
In a preclinical model, c-Fos/AP-1 was shown to be necessary for the induction of the pathological gene program but not critical for cardiomyocyte hypertrophy itself.
Answers are grounded in this paper and cite their sources.
Decouples hypertrophic growth from pathological gene expression in myocytes; leaves open selective c-Fos targeting for remodeling in vivo.
BACKGROUND: Although induction of activator protein-1 (AP-1) transcription factor activity has been observed in cardiac hypertrophy, a direct role for AP-1 in myocardial growth and gene expression remains obscure. METHODS AND RESULTS: Hypertrophy was induced in cultured neonatal rat cardiomyocytes with phenylephrine or overexpression of a constitutively active MAP3K, MKK6. In both treatment groups, induction of the pathological gene profile was observed, ie, expression of beta-myosin heavy chain (betaMHC), atrial/brain natriuretic peptides (ANP/BNP), and skeletal alpha-actin (sACT) was increased, whereas expression for alpha-myosin heavy chain (alphaMHC) and the sarcoplasmic reticulum Ca2+-ATPase (SERCA) genes was repressed. The role of AP-1 in the hypertrophic phenotype was evaluated with the use of an adenoviral construct expressing a dominant negative mutant of the c-Fos proto-oncogene (AdAFos). Although AFos did not change the myocyte growth response, it abrogated the gene profile to both agonists, including the upregulation of both alphaMHC and SERCA expression. CONCLUSIONS: Although c-Fos/AP-1 is necessary for induction of the pathological/fetal gene program, it does not appear to be critical for cardiomyocyte hypertrophy.
No takes yet. Share an insight, caveat, or question.
Jeong et al. (2005) studied Cardiac hypertrophy. Dominant negative mutant of the c-Fos proto-oncogene (AdAFos) was evaluated on Myocyte growth response and pathological gene profile expression. Expression of a dominant negative mutant of c-Fos (AFos) abrogated the pathological gene profile induced by hypertrophic agonists but did not change the myocyte growth response.
Synapse has enriched 10 related papers. Consider them for comparative context: